Custom Health Featured in Cantech Letter Following Stifel Analyst Initiation
Custom Health was recently featured in a Cantech Letter article highlighting Stifel's initiation of coverage with a "Buy" rating and a $12.00 price target, with the analyst noting potential upside to $18.00 per share.
According to the article, Stifel believes Custom Health is well positioned for growth, citing:
- 98% medication adherence achieved through the Company's integrated platform.
- Approximately 100,000 patients, with significant patient growth expected.
- Expected revenue growth of more than 100%, supported by the InnovativeRx acquisition and continued platform expansion.
The article highlights Stifel's investment thesis, recognizing Custom Health's differentiated platform that combines its proprietary AdhereNet® software, AI-powered clinical solutions, automated pharmacy network, and Spencer® in-home medication dispensing system to address medication non-adherence, a healthcare challenge estimated to cost the U.S. system US$500 billion annually.
